AzTrials
AzTrials

Chronic Rhinosinusitis (CRS) with and Without Nasal PolypsNCT06737198

Correlation of Preoperative Indices (serum Vit D, Calcium, Phosphorus, FAR, PLR, SII) on Intraoperative Bleeding in CRS

An observational study of Chronic Rhinosinusitis (CRS) with and Without Nasal Polyps, run by Nanjing First Hospital, Nanjing Medical University at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The purpose of this observational study was to examine whether preoperative indicators correlate with intraoperative bleeding to facilitate control of intraoperative bleeding. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
What is being tested?
without interventios.
How many people
100 participants
Where
1 siteChina
Study dates
1 Nov 2024to 31 Mar 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Diagnosed with chronic sinusitis

Who may be able to join

  • Clinical diagnosis of chronic rhinosinusitis

Who cannot join

  • Sinus cyst Upper respiratory tract infection in the last 1 week Use of antiepileptic drugs Use of aspirin Use of anticoagulant or antiplatelet drugs

Trial locations and contacts

1 site in 1 country.

China1 site
  • Nanjing First Hospital

    Nanjing, Jiangsu, 210006

Other trials in China

About this study

The purpose of this observational study was to examine whether preoperative indicators correlate with intraoperative bleeding to facilitate control of intraoperative bleeding.

Read the detailed description

In this study, we analysed the effect of preoperative inflammation on intraoperative haemorrhage at the subjective and objective levels by measuring a number of indicators (including Vit D, Ca, P, and some ratios) in the blood specimens and by three scales.Blood test indicators can be obtained from routine tests.Three scales were obtained by the researcher after interviewing the patients, Symptom Score (0-15), where higher scores indicate more severe symptoms, Lund-Kennedy Score (0-6), where higher scores indicate higher levels of localised inflammation, Lund-Mackay Score (0-12 unilaterally and 24 bilaterally), where higher scores indicate higher levels of inflammation, and Lund-Mackay Score (0-12 unilaterally and 24 bilaterally), where higher scores indicate higher levels of inflammation.Lund-Mackay score (0-12 unilaterally, 24 bilaterally), where higher scores represent higher levels of inflammation.Final correlation of blood test indices and three scale scores with intraoperative.

Being tested
without interventios.
Keywords
chronic rhinosinusitis, Intraoperative haemorrhage
Medical subject headings
Blood Loss, Surgical

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • without interventios.Other

    without interventios.

Study groups in NCT06737198
Study groupRoleWhat they receive
chronic rhinosinusitischronic rhinosinusitis with/without nasal polys.
Receives: Other: without interventios.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraoperative haemorrhage

    Intraoperative haemorrhage was grouped with a cut-off value of 150 ml and divided into <150 ml (normal haemorrhage group) and ≥150 ml (high haemorrhage group).

    Measured: 2024/11/1-2025/7/31

Secondary outcomes (3)
  1. Symptom system

    Symptom system (0-15 scores), assessed in five areas: nasal congestion, runny nose, reduced sense of smell, head and face swelling, and sleep disturbances, where higher scores represent more severe symptoms.

    Measured: 2024/11/1-2025/7/31

  2. Lund-Kennedy system

    Lund-Kennedy system (0-6 scores), assessed under nasal endoscopy in terms of polyps, oedema and nasal secretions, where a higher score represents a higher level of local inflammation.

    Measured: 2024/11/1-2025/7/31

  3. Lund-Mackay system

    The Lund-Mackay system (0-12 unilaterally, 24 points in total bilaterally) analyses the inflammatory status within each sinus and the assessment of whether the sinonasal complex is obstructed in two major ways, where higher scores represent higher levels of inflammation.

    Measured: 2024/11/1-2025/7/31

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2024
  2. Study start1 Nov 2024
  3. Primary completion31 Jul 2025 (estimated)
  4. Study completion31 Mar 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06737198
Sponsor's protocol ID
KY20241112-07
Status last verified
Nov 2024
First submitted
3 Dec 2024
Last updated
17 Dec 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Rhinosinusitis (CRS) with and Without Nasal Polyps, run by Nanjing First Hospital, Nanjing Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 17 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraoperative haemorrhage (time frame: 2024/11/1-2025/7/31). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in